Initiator Pharma A/S Cash Flow Conversion Efficiency
Initiator Pharma A/S cash flow conversion efficiency. Based on the latest financial reports, Initiator Pharma A/S (INIT) has a cash flow conversion efficiency ratio of -0.144x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.68 Million ≈ $-504.13K USD) by net assets (Skr32.47 Million ≈ $3.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Initiator Pharma A/S (2016–2024)
Cash flow conversion efficiency of Initiator Pharma A/S from 2016 to 2024. This chart illustrates how Initiator Pharma A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Initiator Pharma A/S stock price today for real-time trading data and today's change.
Initiator Pharma A/S Cash Flow Conversion Ratio Explained
Initiator Pharma A/S cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Initiator Pharma A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Initiator Pharma A/S ranked by their cash flow conversion efficiency. Also see INIT stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inbest Prime III Inmuebles SOCIMI S.A.
MC:YINB3
|
N/A |
|
Wilton Resources Inc
V:WIL
|
-1.093x |
|
Image Resources NL
AU:IMA
|
0.024x |
|
StarFlex Co. Ltd
KQ:115570
|
-0.017x |
|
Giyani Metals Corp
V:EMM
|
-0.058x |
|
Greenland Mines Ltd
NASDAQ:GRML
|
-0.113x |
|
TCS Group Holdings Bhd
KLSE:0221
|
-0.150x |
|
Purefun Group AB
ST:PURE
|
0.088x |
Annual Cash Flow Conversion Efficiency for Initiator Pharma A/S (2016–2024)
The table below shows the annual cash flow conversion efficiency of Initiator Pharma A/S from 2016 to 2024. Review INIT free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr14.78 Million ≈ $1.59 Million |
Skr-12.08 Million ≈ $-1.30 Million |
-0.817x | +48.31% |
| 2023-12-31 | Skr11.16 Million ≈ $1.20 Million |
Skr-17.65 Million ≈ $-1.90 Million |
-1.581x | -64.49% |
| 2022-12-31 | Skr34.02 Million ≈ $3.66 Million |
Skr-32.70 Million ≈ $-3.52 Million |
-0.961x | +1.36% |
| 2021-12-31 | Skr34.99 Million ≈ $3.77 Million |
Skr-34.10 Million ≈ $-3.67 Million |
-0.974x | -74.10% |
| 2020-12-31 | Skr14.41 Million ≈ $1.55 Million |
Skr-8.06 Million ≈ $-867.82K |
-0.560x | +35.17% |
| 2019-12-31 | Skr9.91 Million ≈ $1.07 Million |
Skr-8.55 Million ≈ $-920.44K |
-0.863x | -5.32% |
| 2018-12-31 | Skr16.57 Million ≈ $1.78 Million |
Skr-13.58 Million ≈ $-1.46 Million |
-0.820x | +37.20% |
| 2017-12-31 | Skr5.96 Million ≈ $641.82K |
Skr-7.78 Million ≈ $-837.68K |
-1.305x | -372.03% |
| 2016-12-31 | Skr-371.00K ≈ $-39.93K |
Skr-178.00K ≈ $-19.16K |
0.480x | -- |
About Initiator Pharma A/S
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to t… Read more